Forbes - Markets
How Biosimilars Can Impact Pharma Company Valuations
An inflexion point in the pharmaceutical industry has loomed with the approval of Hospira’s biosimilar version of Remicade in Europe and the subsequent approval in the U.S. of its first biosimilar, Novartis’ Zarxio (which targets Amgen’s Neupogen). So far, the industry has encountered patent cliffs due to generic versions of small molecule drugs hitting the market, with biologics remaining well protected due to lack of appropriate approval guidelines. While we believe that a lot of stake holders will benefit from the advent of biosimilars, some will be adversely affected.
No comments:
Post a Comment